OLX-101A is under clinical development by OliX Pharmaceuticals and currently in Phase II for Hypertrophic Scars. According to GlobalData, Phase II drugs for Hypertrophic Scars does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OLX-101A LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OLX-101A overview
OLX-101A (BMT-101) is under development for the treatment of hypertrophic scar. It is administered topically, intradermally and through subcutaneous routes. The drug candidate is a second generation siRNA which that acts by targeting connective tissue growth factor genes. It is based on the cp-lasiRNA technology.
The drug candidate was also under development for the treatment of idiopathic pulmonary fibrosis and senile (age related) macular degeneration.
OliX Pharmaceuticals overview
OliX Pharmaceuticals a clinical-stage biotechnology company that carries out the discovery and development of RNA interference (RNAi) therapeutics. The company’s pipeline products include OLX101A treats hypertrophic scar treatment; OLX104C targets male pattern hair loss treatment; OLX301A is for the treatment of age-related macular degeneration; OLX301D for subretinal fibrosis; OLX702A treats metabolic abnormal steatohepatitis; OLX703A is for the treatment of Hepatitis B Virus (HBV). The company operates in South Korea and the US. Olix Pharmaceuticals is headquartered in Suwon, South Korea.
For a complete picture of OLX-101A’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
